Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia

americanpharmaceuticalreviewJune 27, 2018

Tag: Revance , Aspen , Phase 3

PharmaSources Customer Service